BRPI0917411A2 - composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit. - Google Patents

composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.

Info

Publication number
BRPI0917411A2
BRPI0917411A2 BRPI0917411A BRPI0917411A BRPI0917411A2 BR PI0917411 A2 BRPI0917411 A2 BR PI0917411A2 BR PI0917411 A BRPI0917411 A BR PI0917411A BR PI0917411 A BRPI0917411 A BR PI0917411A BR PI0917411 A2 BRPI0917411 A2 BR PI0917411A2
Authority
BR
Brazil
Prior art keywords
cell
subject
rassf1a
cells
dansyl
Prior art date
Application number
BRPI0917411A
Other languages
English (en)
Portuguese (pt)
Inventor
Kathryn D Sheikh
Mikell Paige
Milton L Brown
Partha Banerjee
Shankar Jagadeesh
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of BRPI0917411A2 publication Critical patent/BRPI0917411A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Electroluminescent Light Sources (AREA)
BRPI0917411A 2008-08-15 2009-08-14 composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit. BRPI0917411A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18905908P 2008-08-15 2008-08-15
PCT/US2009/004681 WO2010019271A1 (en) 2008-08-15 2009-08-14 Fluorescent regulators of rassf1a expression and human cancer cell proliferation

Publications (1)

Publication Number Publication Date
BRPI0917411A2 true BRPI0917411A2 (pt) 2015-12-01

Family

ID=41279343

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917411A BRPI0917411A2 (pt) 2008-08-15 2009-08-14 composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.

Country Status (9)

Country Link
US (1) US10457639B2 (enExample)
EP (2) EP2484666A1 (enExample)
JP (2) JP2012500197A (enExample)
CN (1) CN102186820B (enExample)
AT (1) ATE547403T1 (enExample)
AU (1) AU2009282451B2 (enExample)
BR (1) BRPI0917411A2 (enExample)
CA (1) CA2734225A1 (enExample)
WO (1) WO2010019271A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
ES2641642T3 (es) 2010-03-08 2017-11-10 Monsanto Technology Llc Moléculas de polinucleótido para regulación génica en plantas
US8637679B2 (en) 2011-03-11 2014-01-28 Council Of Scientific And Industrial Research Process for the isolation of organic compounds useful for the treatment of cancer
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
MX342856B (es) 2011-09-13 2016-10-13 Monsanto Technology Llc Metodos y composiciones para el control de malezas.
CN103974967A (zh) 2011-09-13 2014-08-06 孟山都技术公司 用于杂草控制的方法和组合物
UA116089C2 (uk) 2011-09-13 2018-02-12 Монсанто Текнолоджи Ллс Спосіб та композиція для боротьби з бур'янами (варіанти)
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
EP3434779A1 (en) 2011-09-13 2019-01-30 Monsanto Technology LLC Methods and compositions for weed control
BR112014005958A2 (pt) 2011-09-13 2020-10-13 Monsanto Technology Llc métodos e composições químicas agrícolas para controle de planta, método de redução de expressão de um gene accase em uma planta, cassete de expressão microbiana, método para fazer um polinucleotídeo, método de identificação de polinucleotídeos úteis na modulação de expressão do gene accase e composição herbicida
US10240161B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
WO2014106837A2 (en) 2013-01-01 2014-07-10 A. B. Seeds Ltd. ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
EP2971185A4 (en) 2013-03-13 2017-03-08 Monsanto Technology LLC Methods and compositions for weed control
BR112015022797A2 (pt) 2013-03-13 2017-11-07 Monsanto Technology Llc método para controle de ervas daninhas, composição herbicida, cassete de expressão microbiano e método de produção de polinucleotídeo
WO2014151317A1 (en) * 2013-03-15 2014-09-25 Rush University Medical Center Methods for treating cancer
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
RU2703498C2 (ru) 2013-07-19 2019-10-17 Монсанто Текнолоджи Ллс Композиции и способы борьбы с leptinotarsa
HUE070313T2 (hu) 2013-11-04 2025-05-28 Greenlight Biosciences Inc Ízeltlábú paraziták és kártevõfertõzöttség szabályozására szolgáló készítmények és eljárások
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
AU2015206585A1 (en) 2014-01-15 2016-07-21 Monsanto Technology Llc Methods and compositions for weed control using EPSPS polynucleotides
BR112016022711A2 (pt) 2014-04-01 2017-10-31 Monsanto Technology Llc composições e métodos para controle de pragas de inseto
US10988764B2 (en) 2014-06-23 2021-04-27 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
EP3161138A4 (en) 2014-06-25 2017-12-06 Monsanto Technology LLC Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
RU2021123470A (ru) 2014-07-29 2021-09-06 Монсанто Текнолоджи Ллс Композиции и способы борьбы с насекомыми-вредителями
JP6942632B2 (ja) 2015-01-22 2021-09-29 モンサント テクノロジー エルエルシー Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
EP3302030A4 (en) 2015-06-03 2019-04-24 Monsanto Technology LLC METHOD AND COMPOSITIONS FOR INTRODUCING NUCLEIC ACIDS IN PLANTS
US10173978B2 (en) * 2015-08-05 2019-01-08 Georgetown University Small molecule androgen receptor inhibitors and methods of use thereof
JP7236382B2 (ja) * 2017-06-12 2023-03-09 昇平 宮田 抗癌剤及びその使用
CN107266356B (zh) * 2017-07-25 2020-06-26 山西省生物研究院有限公司 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2235815A1 (de) * 1972-07-21 1974-01-31 Bayer Ag Polyazofarbstoffe
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
GB9215361D0 (en) 1992-07-20 1992-09-02 Wellcome Found Heterocyclic compounds
ATE225334T1 (de) 1993-07-26 2002-10-15 Eisai Co Ltd Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring
JP3690825B2 (ja) * 1993-07-26 2005-08-31 エーザイ株式会社 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体
CA2186412A1 (en) 1995-10-31 1997-05-01 Katherine S. Takaki Ethylamino carbazole melatonergic agents
WO1999032463A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
EP1184373A4 (en) 1999-04-20 2004-10-20 Meiji Seika Kaisha TRICYCLIC CONNECTIONS
AU1888501A (en) 1999-12-16 2001-06-25 Asahi Kasei Kabushiki Kaisha Novel substituted tricyclic compounds
WO2001083452A1 (en) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
JP4224566B2 (ja) 2000-12-18 2009-02-18 株式会社医薬分子設計研究所 炎症性サイトカイン産生遊離抑制剤
AU2002228316A1 (en) 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
JPWO2002074306A1 (ja) 2001-03-19 2004-07-08 旭化成ファーマ株式会社 脂肪肝治療薬
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
WO2006002908A1 (en) 2004-06-29 2006-01-12 Jadolabs Gmbh Carbazole-derived pharmaceutical compositions
CA2575046A1 (en) 2004-08-18 2006-02-23 Ciba Specialty Chemicals Holding Inc. Oxime ester photoinitiators
ITMI20051523A1 (it) * 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
DE112006002340T5 (de) 2005-09-01 2008-07-17 Council Of Scientific And Industrial Research Arzneimittel, verwendbar zur Behandlung von Prostatakrebs
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
ZA200803226B (en) * 2005-10-13 2009-11-25 Orchid Res Lab Ltd Heterocyclic Compounds as Pstat3/IL-6 Inhibitors
US20100130579A1 (en) * 2006-10-23 2010-05-27 Georgetown University Cancer therapy
IL186935A0 (en) * 2006-10-31 2008-02-09 Veridex Llc Prostate cancer field effect analysis methods and kits
EP2238265A4 (en) * 2007-12-28 2012-01-18 Wayne John Cancer Inst USE OF THE METHYLATION STATE OF MINT-LOCI AND TUMOR ASSOCIATED GENES AS A MARKER FOR MELANOMA AND MAMMARIAN CARCINOMA
AU2009228765B2 (en) 2008-03-24 2012-05-31 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
US20110152339A1 (en) 2011-06-23
WO2010019271A1 (en) 2010-02-18
EP2484666A1 (en) 2012-08-08
CN102186820A (zh) 2011-09-14
EP2323982A1 (en) 2011-05-25
US10457639B2 (en) 2019-10-29
AU2009282451A1 (en) 2010-02-18
CN102186820B (zh) 2013-08-28
ATE547403T1 (de) 2012-03-15
JP2012500197A (ja) 2012-01-05
EP2323982B1 (en) 2012-02-29
JP2014148545A (ja) 2014-08-21
CA2734225A1 (en) 2010-02-18
WO2010019271A8 (en) 2011-03-31
AU2009282451B2 (en) 2014-02-13
HK1158206A1 (en) 2012-07-13

Similar Documents

Publication Publication Date Title
BRPI0917411A2 (pt) composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.
Zhou et al. Inorganic–organic hybrid nanoprobe for NIR‐excited imaging of hydrogen sulfide in cell cultures and inflammation in a mouse model
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
EA201101585A1 (ru) 3-(1,2,3-триазол-4-ил)пирроло[2,3-b]пиридинпроизводные
ATE513832T1 (de) 8-anilinoimidazopyridine und ihre verwendung als antikrebsmittel und/oder entzündungshemmende mittel
EA201290389A1 (ru) Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
PH12013502369A1 (en) Diazacarbazoles and methods of use
MX2010003368A (es) Derivados de imidazol.
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
ECSP088598A (es) Derivados de piridazinona
ZA200701137B (en) Triazolophthalazines
BRPI0518198B8 (pt) método ex vivo para tratar uma composição de células hemácias para inativar um patógeno, se presente, bem como composição e kit
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
WO2009153774A3 (en) Compositions and methods for prognosis of ovarian cancer
ATE487721T1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
ATE502025T1 (de) Arylcarboxamide und ihre verwendung als antitumormittel
MX2021009987A (es) Metodos para el etiquetado de celulas eucariotas de un organismo multicelular utilizando compuestos monosacaridos modificados.
BR0303012A (pt) Avaliação de câncer colorretal
Qi et al. Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma
UA96745C2 (en) PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
LU et al. Expression and clinical significance of Mel-18 mRNA in gastric carcinoma
SHANG et al. Expression of HER-2 and TOPO-Ⅱα in ovarian epithelial cancer and its clinical significance
WU Research progress of thioredoxin reductase 2 in malignant tumor

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]